The Pulmonary Fibrosis Foundation appoints Pauline Bianchi as VP of R&D.
M2 EQUITYBITES-March 6, 2018-The Pulmonary Fibrosis Foundation appoints Pauline Bianchi as VP of R&D
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Pulmonary fibrosis company The Pulmonary Fibrosis Foundation (PFF) revealed on Monday the appointment of Pauline Bianchi, RN, BSN as vice president of its Research and Development.
A veteran nurse and pharmaceutical expert, Bianchi's responsibilities in the company's R&D department includes leading the PFF Care Center Network and PFF Therapeutics Network, to bring high quality care to patients, accelerate the development of clinical trials as well as launch an interstitial lung disease (ILD) nursing network designed to provide training and share knowledge of best practices in ILD with the nursing community across the country.
Most recently, Bianchi has served as senior director of Medical Affairs at Veracyte, a genomics diagnostic company.
Previously, Bianchi was involved in clinical trials for pirfenidone, one of only two US FDA approved drug therapies for IPF (idiopathic pulmonary fibrosis), at InterMune (now Genentech).
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Mar 6, 2018|
|Previous Article:||American Riviera Bank announces new branch in Paso Robles in California.|
|Next Article:||MYM commences construction of the Weedon project upon approval by the Municipality of Weedon, QC, Canada.|